Latest news and articles about إنسيليكو ميديسن from NEX English
Insilico Medicine has announced a collaboration agreement with Eli Lilly worth <strong>$2.75 billion</strong> aimed at developing new drugs. This partnership comes at a time when the pharmaceutical industry is increasingly turning to modern technology for research and development.
Eli Lilly has announced a new partnership with Insilico Medicine aimed at developing drugs entirely designed by artificial intelligence. The deal, valued at approximately <strong>$2.75 billion</strong>, will enhance the company's efforts in discovering new treatments for various diseases.
Insilico Medicine, listed in Hong Kong, has announced a strategic partnership with American company Eli Lilly to develop new drugs using artificial intelligence technologies. The deal could be worth up to $2.75 billion, with an initial payment of $115 million.
Insilico Medicine has announced an expansion of its partnership with Eli Lilly in a deal valued at $2.75 billion, focusing on AI-driven drug discovery. Eli Lilly will leverage Insilico's AI engine to gain exclusive licenses for developing new treatments.